PTSD biomarkers: Neuroendocrine signaling to epigenetic variants
Date
2024
Authors
Sbisa, A.
Graham, K.
Lawrence-Wood, E.
McFarlane, A.C.
Toben, C.
Editors
Makowski, G.
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Book chapter
Citation
Advances in Clinical Chemistry, 2024 / Makowski, G. (ed./s), vol.122, Ch.6, pp.209-260
Statement of Responsibility
Conference Name
Abstract
Posttraumatic stress disorder (PTSD) is characterized by exposure to traumatic events and involves symptom domains such as intrusive thoughts, avoidant behaviors, negative mood, and cognitive dysfunction. The disorder can be chronic and debilitating, and the heterogenous nature and varied presentation of PTSD has afforded difficulty in determining efficacious treatment. The ability to identify biomarkers for PTSD risk, prognosis, or for the purposes of treatment, would be highly valuable. There is evidence for peripheral biomarkers related to the hypothalamic-pituitary-adrenal axis, the immune system, neurotransmitters and neurohormones, while genome and epigenome wide association studies have identified genes of interest relating to neurocircuitry, monoaminergic function, and the immune system. Importantly, however, reproducibility is a persistent issue. Considerations for future research include the need for well-powered and well-designed studies to determine directionality, in addition to considering biomarkers as they relate to symptom domains and the spectrum of symptom severity rather than dichotomous diagnostic outcomes. We conclude by recommending the staging of biological processes and PTSD symptoms, from subsyndromal to chronic, which could eventually facilitate selection of personalized treatment interventions for individuals with PTSD, in addition to serving as a future framework for biomarker data.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2024 Elsevier